DrugCendR

DrugCendR Inc. to Present Phase I Plans on 2 Occasions During the JP Morgan Healthcare Conference in San Francisco Next Week

As DrugCendR is now preparing to transition from a preclinical to a clinical-stage company, the company will present details on their Phase I–ready lead compound CEND-1 – a highly innovative molecular mimicry agent that is able to activate a drug transport mechanism specifically in solid tumors. To date, there are more than 100 studies using DrugCendR’s proprietary technology, providing an unprecedented amount of preclinical validation / proof-of-concept. - January 04, 2018